Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-439.3%-99.1pp-340.2%-20.8pp-319.3%-58.6pp-260.8%+148pp-408.9%-18.3pp
Net margin-411.4%-96.5pp-314.9%-22.4pp-292.5%-57.9pp-234.6%+135pp-369.4%-14.5pp
EBITDA margin-427.3%-97.5pp-329.8%-21.4pp-308.4%-58.4pp-250%+142pp-391.8%-18.4pp
Free cash flow margin-378.7%-65.0pp-313.7%-25.3pp-288.4%
Returns
Return on equity-61.4%-11.8pp-49.6%+15.7pp-65.4%-14.7pp-50.7%+13.5pp-64.2%-10.9pp
Return on assets-47.2%-8.2pp-39%+8.3pp-47.3%-9.6pp-37.6%+7.3pp-44.9%-7.2pp
Return on invested capital-70.2%+2.0pp-72.2%+9.6pp-81.8%-15.6pp-66.2%+13.6pp-79.8%-11.1pp
Efficiency
Asset turnover0.1×0.0×0.1×0.0×0.2×0.0×0.2×0.0×0.1×0.0×
Liquidity
Current ratio-1.0×+1.7×5.4×-1.5×6.8×+0.6×6.3×-0.2×
Quick ratio-1.0×+1.7×5.4×-1.5×6.8×+0.6×6.3×-0.2×
Cash ratio0.8×-2.1×2.9×+1.9×-0.2×1.1×+0.3×0.9×-0.3×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.2×0.0×0.1×+0.1×0.1×0.0×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.0×
Per Share
Book value per share$4.37-29.7%$6.22+40.5%$4.42-17.1%$5.34-7.3%$5.76-26.7%
Valuation
Market capitalization$1.64B-8.4%$1.79B+151%$714.04M-4.1%$744.82M-36.5%$1.17B-27.1%
Enterprise value$1.63B+1.8%$1.6B+132%$691.12M-2.9%$711.59M-36.6%$1.12B-26.5%
Price / sales22.9×+1.5×21.3×+12.8×8.5×+0.1×8.4×-12.4×20.8×-8.7×
Price / book3.4×+0.1×3.3×+1.4×1.9×+0.3×1.7×-0.8×2.4×-0.6×
EV / sales22.7×+3.6×19.1×+10.8×8.3×+0.2×8.1×-11.8×19.9×-8.1×
Free cash flow yield-16.6%-1.9pp-14.7%+19.1pp-33.8%
Earnings yield-18%-3.2pp-14.8%+19.5pp-34.3%-6.4pp-27.8%-10.1pp-17.8%-5.7pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Nurix Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Nurix Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.